REVIEW ARTICLE

Fifty liver transplants: a single centre experience of haemodynamic management in liver transplantation for cirrhosis [part 2]

B.Gunetilleke¹, R.Ranamuni¹, D.Jayaweera¹, N.Welikala¹, V.Kerner¹, N.Munasinghe¹, R.Withanage¹, N.Wickremasinghe¹, S.Hewage¹, N.Wijesuriya¹, U.Rodrigo¹, A.Mudalige¹, M. Fernando¹, D.Hettiarchchi¹, J.Dissanayake¹, M.Niriella¹, A.Dassanayake¹, R.Wijesuriya¹, C.Liyanage¹, S.Thilakaratne¹, R.Siriwardana¹, J. De Silva¹
¹Colombo North Center for Liver Disease, Faculty of Medicine, University of Kelaniya, Sri Lanka
²Faculty of Medicine, University of Colombo, Sri Lanka

Keywords: Liver transplantation; cirrhosis; non-alcoholic fatty liver disease; alcohol related liver disease

Abstract
Globally, an estimated one million deaths occur annually due to complications of cirrhosis. Cirrhosis with end stage liver disease [ESLD] is a leading cause death due to non-communicable diseases in Sri Lanka. Non-alcoholic fatty liver disease [NAFLD] and alcohol related liver disease [ARLD] are the principal causes of ESLD due to cirrhosis in Sri Lanka. Liver transplantation remains the only curative treatment for such patients. Multiorgan dysfunction and hemodynamic instability characteristic of ESLD adds to the complexity of perioperative care in liver transplantation. Maintenance of stable hemodynamics including optimal hemostasis forms the core of the anaesthetic strategy in liver transplantation.

1. Introduction
Advances in hemodynamic management have contributed significantly to excellent outcomes following liver transplantation for ESLD in high volume centers. Despite limited resources the team at CNCLD strives to adopt an evidence-based approach to haemodynamic management in liver transplant. This approach coupled with innovation and perseverance have been key factors that enabled the team at CNCLD which carried out the first liver transplant in 2011, achieve the milestone of fifty liver transplants in 2020.

2. Haemodynamic monitoring
Haemodynamic instability [HDI] during liver transplant [LT] is a risk factor for major adverse cardiovascular events, graft dysfunction and death. Multiple factors including fluctuations in cardiac preload, contractility, afterload, arrhythmia, electrolyte disturbance, and factors related to the graft result in HDI.

Monitoring of invasive arterial and central venous pressure, urine output, blood gases, lactate, electrolytes, and coagulation supplemented by advanced hemodynamic monitoring is essential to identify and treat HDI during LT.

The pulmonary artery catheter [PAC] remains a valuable tool particularly in patients with porto-pulmonary hypertension . Mixed venous oxygen saturation though traditionally used as a measure of oxygen supply-demand balance, correlates poorly with cardiac output in liver transplantation.

Trans-esophageal echocardiography [TEE] is used owing to its versatility in providing real-time information on intra cardiac flow, volume and pressure, structure, function, and the presence of embolic material. This information is not readily available with other types of haemodynamic monitors. The inability to measure rapid changes in pulmonary and systemic vascular resistance are significant limitations of TEE. Access to PAC and TEE at CNCLD is limited by cost and logistical factors.

Calibrated pulse wave analysis based hemodynamic monitors e.g., PiCCO [Pulse index continuous cardiac output], LiDCO plus [Lithium dilution cardiac output] provides clinically useful information in the setting of LT. Rapid changes in vascular resistance and the presence of vasoactive drugs in LT, limits the usefulness of uncalibrated pulse wave analysis-based monitors including Flowtrac®. Esophageal Doppler cardiac output monitor is a useful adjunct to other advanced haemodynamic monitors in stable cirrhotics . Due to limited resource a combination uncalibrated cardiac output monitors, Flowtrac® or LiDCO rapid® and esophageal doppler are used to guide hemodynamic therapy for LT at CNCLD. Delays in procuring disposables limits our ability to use a uniform monitoring protocol.

3. Haemodynamic management
Specific strategies are required to manage hemodynamic derangement unique to the pre-anhepatic [dissection], anhepatic and reperfusion phases. A goal directed strategy targeting volume responsiveness, cardiac output and stroke volume is associated with a less positive fluid balance, reduced duration of post-operative ventilation and reduced length of ileus . A restrictive fluid strategy combined with vasopressors, facilitates low central venous pressure [CVP], reduction of portal venous pressure, intraoperative bleeding,
The use of synthetic starch colloid solutions in critically ill patients has been associated with an increase in the need for renal replacement therapy. The use of synthetic starch solutions in liver transplant is not widespread in the absence of robust evidence regarding its safety in this setting.

At CNCLD, all intravenous fluids are infused via a rapid infuser which delivers fluid at 37°C, at rates of up to 750ml/minute. Inline volume and pressure monitors and air detection systems are useful safety features incorporated in this device.

### 5. Vasopressors

Restrictive use of intravenous fluid results in greater dependence on vasopressors to maintain hemodynamic stability. Though the use of vasopressors, preoperative renal dysfunction and postoperative anemia have been identified as predictors of early post LT renal dysfunction, this relationship may reflect severity of underlying ESLD and the requirement for vasopressors rather than causality.

Terlipressin, a splanchnic vasoconstrictor improves renal perfusion, reduces the risk of post-operative acute kidney injury [AKI], small for size graft syndrome and is used in the management of portal hypertension.

Vasopressors have a volume sparing effect. This results in a lower fluid balance at the end of LT. This is true even of older patients with higher MELD scores, larger blood loss, given greater volumes of blood products. A reduced positive fluid balance was associated with a lower incidence of postoperative acute kidney injury; shorter duration of ventilation and ICU stay. In patients with a positive fluid balance, use of vasopressors reduced the need for renal replacement therapy and improved 1 year mortality. Noradrenaline [NE] is preferred to dopamine, adrenaline, and vasopressin as the first line vasopressor. The low endogenous vasopressin levels in ESLD results in a rapid response to exogenous vasopressin. Vasopressin is useful in managing the vasoplectic syndrome, which occurs predominantly in the reperfusion phase of liver transplantation.

Vasopressin is synergistic with NE and is added when NE dose exceeds 0.1 µg/kg/min.

### 6. Inotropes

The combination of a preoperative ejection fraction less than 50%, prolongation of QT interval and diastolic dysfunction is strongly suggestive of underlying cirrhotic cardiomyopathy. Left and right ventricular dysfunction are common, particularly during reperfusion. Dobutamine is the inotrope of choice at CNCLD. Inhaled nitric oxide, prostaeyclin,
Figure 1. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.

[Courtesy: Journal of Thrombosis and Haemostasis, Volume: 19, Issue: 4, Pages: 1116-1122, First published: 31 March 2021, DOI: 10.1111/jth.15239]
intravenous milrinone and extracorporeal membrane oxygenation [ECMO] have been used to treat portopulmonary hypertension.

7. Rebalanced hemostasis and management of coagulation

Chronic end stage liver disease is characterized by derangements in primary and secondary hemostasis and fibrinolysis [Figure 1].

ESLD is characterized by re-balanced hemostasis with reduced hemostatic reserve [Fig 1]. This precarious balance could tilt to a hyper or hypocoagulable state induced by stressors including surgery, infection, or ischemia-reperfusion injury. Standard tests of coagulation; platelet count, prothrombin time [PT], activated partial thromboplastin time [APTT] and fibrinogen levels are of limited value in complex acquired disorders of hemostasis as seen in ESLD. PT is unaffected by changes in levels of protein C and S. Use of PT and INR to guide correction of coagulopathy in ESLD results in over correction of coagulopathy.

Increased levels of Von Willebrand factor [VWF] and reduction of VWF cleavage protein ADAMTS-13 predisposes to thrombosis despite thrombocytopenia [18]. Hyperfibrinolysis is not readily detected by standard tests of coagulation. Hyperfibrinolysis during the pre-anhepatic phase and fulminant hyperfibrinolysis with diffuse bleeding in the anhepatic and reperfusion phases should be treated with antifibrinolytics. Hyperfibrinolysis in the reperfusion phase is usually self-limiting and resolves spontaneously. Resolution of hyperfibrinolysis is an early indicator of graft function. In the absence of profuse bleeding, prophylactic use of hemostatic products prior to invasive procedures and liver transplantation is not recommended.

Dynamic, whole blood point of care viscoelastic hemostasis tests [VHT] such as Thromboelastography [TEG®] and rotational thromboelastometry [ROTEM®] indicates the status of clot formation, clot strength and fibrinolysis within a short turnaround time. VHT guided hemostatic therapy does not increase the risk bleeding or thrombotic complications [19].

VHTs reliably predict bleeding and need for blood products in LT resulting in reduced usage of blood products, a lower rate of complications and improved survival after LT [19].

ROTEM, EXTEM MCF correlates with platelet count and fibrinogen levels. EXTEM A5, an early indicator of impaired clot firmness secondary to critically low levels of platelets and fibrinogen levels, is a good linear predictor of EXTEM MCF. FIBTEM MCF which correlates with fibrinogen levels is used to differentiate low platelet count from a low fibrinogen level, as the cause of impaired clot firmness [20, 21].

The lack of facilities for Point-of-care VHT testing within the operation theatre complex at CNCLD limits its usefulness in managing rapidly evolving coagulopathy.

8. Transfusion of blood products

Advances in surgery, anaesthesia and VHT guided coagulation therapy have revolutionized management of bleeding in liver transplantation. Increased requirement for blood products could reflect coagulopathy and severity of underlying ESLD. VHT guided management of coagulation reduces the risks of fluid overload, raised pulmonary arterial and portal venous pressure and adverse effects attributed to blood products [22-24].

The use of FFP in LT needs to be considered carefully due to concerns regarding its safety, and lack of evidence of benefit particularly when used to in the setting of impaired thrombin generation [19, 25]. The number of units of packed red cells and the volume of plasma transfused correlates with reduced one year survival following liver transplant [22, 26]. Transfusion related immune modulation and risk of infection, neutrophil-mediated exaggerated inflammatory response to tissue damage and ischemia-reperfusion adversely impact outcome following LT. Red cell transfusion is an independent risk factor for early acute kidney injury post liver transplant [27]. Platelet transfusion is a risk factor for acute lung injury, graft injury and correlates strongly with poor post-transplant outcome [22, 28-30].

Advances in perioperative care, evidence linking blood products with adverse outcomes, use of protocols based on VHT and the availability of factor concentrates have led to a reduction in transfusion requirements [19, 31]. At CNCLD, management of coagulopathy in LT is based on the Essen University A5 protocol [19]. The use of platelet concentrates and fresh frozen plasma is restricted to patients with significant bleeding and is guided by VHT. Cryoprecipitate use as the source of fibrinogen is guided by VHT, in the presence of clinically significant bleeding. The use of factor concentrates is limited due to high cost. Leukocyte depleted red blood cell transfusion is based on need.

9. Enhanced recovery after liver transplant surgery

Adoption of a protocol of evidence-based interventions including the use of advanced hemodynamic monitoring, adherence to a restrictive fluid protocol, viscoelastic test guided use of blood products and monitoring the depth of anaesthesia has resulted in improved outcome following LT.
Adoption of such a protocol is associated with early extubation, early mobilization, reduction of postoperative ventilation, postoperative complications, length of intensive care and hospital stay and cost. Adoption of the protocol has been linked to a rapid pace of recovery even in the sicker, high MELD patients [32-34].

Achievement of enhanced recovery following LT is a surrogate marker of the quality of perioperative care. Since adoption of this strategy, 20% of patients undergoing LT at CNCLD have been extubated in operation theatre and fast tracked to discharge.

10. Summary

Haemodynamic management in liver transplantation for cirrhosis is challenging due to a complex interplay of factors associated with ESLD, liver graft, surgery and anaesthesia. As complex changes in haemodynamics and coagulation in this setting are better understood adoption of evidence based haemodynamic management, haemostatic interventions guided by viscoelastic hemostatic interventions in combination with an enhanced recovery protocol have resulted in improved outcomes following liver transplantation.

All authors disclose no conflict of interest. The study was conducted in accordance with the ethical standards of the relevant institutional or national ethics committee and the Helsinki Declaration of 1975, as revised in 2000.

References

1. Klinck JR, De Wolf A. Liver transplantation: anaesthesia and perioperative care. Oxford Textbook of Transplant Anaesthesia and Critical Care. 2015:223.
   https://doi.org/10.1093/med/9780199651429.003.0022

2. Perilli V, Aceto P, Sacco T, Modesti C, Ciocchetti P, Vitale F, et al. Anaesthesiological strategies to improve outcome in liver transplantation recipients. Eur Rev Med Pharmacol Sci. 2016;20[15]:3172-7.

3. Reydellet L, Blasco V, Mercier M-F, Antonini F, Nafati C, Harti-Souab K, et al., editors. Impact of a goal-directed therapy protocol on postoperative fluid balance in patients undergoing liver transplantation: a retrospective study. Annales francaises d'anesthésie et de réanimation; 2014: Elsevier.
   https://doi.org/10.1016/j.amfar.2013.12.016

4. Massicotte L, Perrault M-A, Denault AY, Landry DW. Vasopressin deficiency and vasodilatory state in end-stage liver disease. Journal of cardiothoracic and vascular anaesthesia. 2012;367[2]:124-34.
   https://doi.org/10.1016/j.jvca.2010.09.018

5. Carrier FM, Chassé M, Wang HT, Aslanian P, Iorio S, Bilodeau M, et al. Restrictive fluid management strategies and outcomes in liver transplantation: a systematic review. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. 2020;67[1]:109-27.
   https://doi.org/10.1007/s12630-019-01480-y

6. Carrier FM, Sylvestre M-P, Massicotte L, Bilodeau M, Chassé M. Effects of intraoperative hemodynamic management on postoperative acute kidney injury in liver transplantation: An observational cohort study. PloS one. 2020;15[8]:e0237503.
   https://doi.org/10.1371/journal.pone.0237503

7. Pfortmueller CA, Funk G-C, Reitterer C, Schrott A, Zotti O, Kabon B, et al. Normal saline versus a balanced crystalloid for goal-directed perioperative fluid therapy in major abdominal surgery: a double-blind randomised controlled study. British journal of anaesthesia. 2018;120[2]:274-83.
   https://doi.org/10.1016/j.bja.2017.11.088

8. Ellekjaer KL, Perner A, Jensen MM, Möller MH. Lactate versus acetate buffered intravenous crystalloid solutions: a scoping review. British Journal of Anaesthesia. 2020.
   https://doi.org/10.1016/j.bja.2020.07.017

9. Shin WJ, Kim YK, Bang JY, Cho SK, Han SM, Hwang GS. Lactate and liver function tests after living donor right hepatectomy: a comparison of solutions with and without lactate. Acta Anaesthesiologica Scandinavica. 2011;55[5]:558-64.
   https://doi.org/10.1111/j.1399-6576.2011.02398.x

10. Dai Wb, Chen Lk, Qi Sy, Pan Zy, Zhang X, Huang Ll, et al. Lactated Ringer's solution versus normal saline in pediatric living donor liver transplantation: A matched retrospective cohort study. Pediatric Anesthesia. 2021;31[6]:702-12.
   https://doi.org/10.1111/pan.14181

11. Huang C-J, Cheng K-W, Chen C-L, Wu S-C, Shih T-H, Yang S-C, et al. Clinical beneficial effects of using crystalloid only in recipients of living donor liver transplantation. International journal of environmental research and public health. 2017;14[11]:1418.
   https://doi.org/10.3390/ijerph14111418

12. Amouzandeh M, Nowak G, Januszkwiewicz A, Wernerman J, Rooyackers O, Norberg Å. Albumin mass balance and kinetics in liver transplantation. Critical Care. 2018;22[1]:1-10.
   https://doi.org/10.1186/s13054-018-2053-6

13. Perner A, Haase N, Guttmannsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's lactate 0.42 in recipients of living donor liver transplantation. Critical Care. 2018;22[1]:1-10.
   https://doi.org/10.1186/s13054-018-2053-6

14. Wiesen P, Massion PB, Joris J, Detry O, Damas P. Incidence and risk factors for early renal dysfunction after liver transplantation. World journal of transplantation. 2016;6[1]:220.
   https://doi.org/10.5500/wjt.v6.i1.220

15. Bezinson D, Mukhtar A, Wagener G, Wray C, Blasi A, Kronish K, et al. Hemodynamic Instability During Liver Transplantation in Patients with End-Stage Liver Disease: A Consensus Document from ILTS, LICAGE, and SATA. Transplantation. 2021.
   https://doi.org/10.1097/TP.0000000000003642

16. Wagener G, Kovalevskaya G, Minhaz M, Mattis F, Emond JC, Landry DW. Vasopressin deficiency and vasodilatory state in end-stage liver disease. Journal of cardiothoracic and vascular anesthesia. 2011;25[4]:665-70.
   https://doi.org/10.1053/j.jvca.2010.09.018

17. Keegan M, Gali B, Brown D, Harrison B, Plevak D, Findlay J, editors. Serum vasopressin concentrations during orthotopic liver transplantation. Transplantation proceedings; 2010: Elsevier.
   https://doi.org/10.1016/j.transproceed.2010.04.051

The Sri Lanka Journal of Surgery 2021; 39(3): 36-42

40
18. Lisman T, Hernandez Gea V, Magnasson M, Roberts L, Stanworth S, Thachil J, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. Journal of Thrombosis and Haemostasis. 2021;19[4]:1116-22. https://doi.org/10.1111/jth.15239

19. Görlinger K, Sakai T, Dirkmann D, Planinsic RM, Yassen K, Saner FH. Bleeding related to liver transplant. Management of Bleeding Patients: Springer; 2021. p. 339-59. https://doi.org/10.1007/978-3-030-56338-7_35

20. Song J-G, Jeong S-M, Jun I-G, Lee H-M, Hwang G-S. Five-minute parameter of thromboelastometry is sufficient to detect thrombocytopenia and hypofibrinogenemia in patients undergoing liver transplantation. British journal of anaesthesia. 2014;112[2]:290-7. https://doi.org/10.1093/bja/aet325

21. Álamo J-M, León A, Mellado P, Bernal C, Marín L, Cepeda C, et al., editors. Is "Intra-operating Room" Thromboelastometry Useful in Liver Transplantation? A Case-Control Study in 303 Patients. Transplantation proceedings; 2013: Elsevier. https://doi.org/10.1016/j.transproceed.2013.11.008

22. de Boer MT, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesthesia & Analgesia. 2008;106[1]:32-44. https://doi.org/10.1213/ane.0b013e3181948a59

23. Hendriks H, Van der Meer J, de Wolf JTM, Peeters P, Porte R, De Jong K, et al. Intraoperative blood transfusion requirement is the main determinant of early surgical re intervention after orthotopic liver transplantation. Transplant international. 2004;17[11]:673-9. https://doi.org/10.1111/j.1432-2277.2004.tb00493.x

24. O’Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019;157[1]:34-43. e1. https://doi.org/10.1053/j.gastro.2019.03.070

25. Levy JH, Grottké O, Fries D, Kozek-Langenecker S. Therapeutic plasma transfusion in bleeding patients: a systematic review. Anesthesia & Analgesia. 2017;124[4]:1268-76. https://doi.org/10.1213/ANE.0000000000001897

26. Biancofiore G, Blasi A, De Boer MT, Franchini M, Hartmann M, Lisman T, et al. Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe [LICAGE]. Minerva anestesiologica. 2019;85[7]:782-98. https://doi.org/10.23736/S0375-9393.19.13468-2

27. Mrzljak A, Franusic L, Pavicic-Saric J, Kelava T, Jurekovic Z, Koćman B, et al. Pre-and intraoperative predictors of acute kidney injury after liver transplantation. World Journal of Clinical Cases. 2020;8[18]:4034. https://doi.org/10.12998/wjcc.v8.i18.4034

28. Hartmann M, Waldé C, Dirkmann D, Saner FH. Safety of coagulation factor concentrates guided by ROTEM™-analyses in liver transplantation: results from 372 procedures. BMC anesthesiology. 2019;19[1]:1-11. https://doi.org/10.1186/s12871-019-0767-x

29. Zheng W, Zhao K-M, Luo L-H, Yu Y, Zhu S-M. Perioperative single-donor platelet apheresis and red blood cell transfusion impact on 90-day and overall survival in living donor liver transplantation. Chinese medical journal. 2018;131[4]:426. https://doi.org/10.4103/0366-6999.225049

30. Pereboom IT, de Boer MT, Haagsma EB, Hendriks HG, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesthesia & Analgesia. 2009;108[4]:1083-91. https://doi.org/10.1213/ane.0b013e3181948a59

31. Zamper RP, Amorim TC, Queiroz VN, Lira JD, Costa LGV, Takaoka F, et al. Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study. BMC anesthesiology. 2018;18[1]:1-12. https://doi.org/10.1186/s12871-018-0664-8

32. Mandell MS, Huang J, Zhao J. Enhanced recovery after surgery and practical application to liver transplantation. Best Practice & Research Clinical Anaesthesiology. 2020;34[1]:119-27. https://doi.org/10.1016/j.bpa.2020.02.001

33. Rodriguez-Laiz GP, Melgar-Requena P, Alcázar-López CF, Franco-Campello M, Villodred-Tudela C, Pascual-Bartolomé S, et al. Fast-Track Liver Transplantation: Six-year Prospective Cohort Study with an Enhanced Recovery After Surgery [ERAS] Protocol. World Journal of Surgery. 2021;45[5]:1262-71. https://doi.org/10.1007/s00268-021-05963-2

34. Biancofiore G, Tomescu DR, Mandell MS, editors. Rapid recovery of liver transplantation recipients by implementation of fast-track care steps: what is holding us Back? Seminars in cardiothoracic and vascular anesthesia; 2018: SAGE Publications Sage CA: Los Angeles, CA. https://doi.org/10.1177/1089253218761124
Annexure 1

Guidance for Haemodynamic Management in Liver Transplantation at the Colombo North Center for Liver Disease (CNCLD)

Preoperative assessment and optimization

- Detailed clinical assessment (ABG if SpO₂ less than 93%)
- Screening test – Six-minute walk distance more than 250m
- Echocardiography – Ejection fraction more than 50% and mean pulmonary arterial pressure below 40mmHg
- Dobutamine stress test, exercise testing, serum creatinine prior to coronary angiogram following multidisciplinary consensus
- Nutritional assessment and optimization
- Graded exercise regime, incentive spirometry
- Counselling

Intraoperative management

- Pre induction ECG, NIBP, SpO₂, forced air warmers
- Femoral and radial intra-arterial blood pressure. Nasopharyngeal thermometer
- Right internal jugular vein: a) Central venous catheter, b) haemodialysis catheter coupled to Belmont™ rapid infuser
- ‘Flowtrac’ / ‘LiDCO’ connected to femoral artery and Oesophageal doppler
- MAP +/- 20% pre-induction pressure
- Cardiac index 2.5 - 3.5L/kg/min
- Stroke volume variation less than 12-15%
- Contractility – Peak velocity (PVel) >65 cm/s
- Systemic vascular resistance index 1500 – 2400 dynes/s/cm²/m²
- Central venous pressure <5 mmHg, Central venous oxygen saturation 60-70% and serum lactate
- Rotational thromboelastometry: Hemostatic therapy of bleeding guided by ROTEM: based on clinical assessment in combination with Essen University A5 protocol
- Sampling for ROTEM: Baseline, 15 minutes prior to anhepatic phase, 15 minutes after caval clamp, 15 minutes prior to reperfusion, 15 minutes, and 45 minutes after reperfusion and 15 prior to extubation or transfer to intensive care unit, 15 min following hemostatic intervention
- Hemoglobin 7-9g/dl
- Urine output 0.5ml/kg/hour
- IV fluid: Compound sodium lactate / 5% albumin (0.9% saline if Na+ < 130meq/l)
- Noradrenaline, dobutamine, vasopressin (Up to 4.8u/hr), calcium gluconate infusions to achieve above targets.
- Vasoplastic syndrome (SVRI < 800 & CI > 5 despite vasopressin 2u/hour and noradrenaline 1mcg/kg/hr) – Methylene blue (1-2mg/kg over 10-15 minutes, 2mg/kg/hour infusion), hydroxocobalamin (125-250mcg bolus / 250-500mcg/hr infusion: Max 5g), Intravenous enriched immunoglobulins
- Coordinate with surgeon to control application and release of vascular clamps
- Boluses of 1:200,000 adrenaline, calcium gluconate during reperfusion
- Consider fast tracking if alert, intact gag reflex, respiratory rate 12-18/minute, normothermic, normal blood gas, no excessive bleeding, nearly normal ROTEM, single vasopressor, noradrenaline dose less than 0.1mcg/kg/min, UOP > 0.5ml/kg/hr

Courtesy: Bhagya Gunetilleke, Colombo North Center for Liver Disease, Faculty of Medicine, University of Kelaniya, Sri Lanka